EU Firsts For CAR-T & PRIME As EMA Grants Kite Accelerated Assessment

Kite Pharma claims it has filed the first EU application to market a CAR T-cell therapy, and says that being on the European Medicines Agency’s PRIME scheme was helpful when it came to getting answers to the questions it had on the application.